JNK-IN-14 

JNK-IN-14 is a potent JNK inhibitor with IC₅₀ values of 1.81, 12.7 and 10.5 nM for JNK1, JNK2 and JNK3, respectively. JNK-IN-14 induces early-stage apoptosis. JNK-IN-14 shows cell population arrest at the G2/M phase and slightly inhibits beclin-1 production at K562 leukemia cells relative to SP600125 (HY-12041), showing higher inhibitory ability.^[1]

JNK-IN-14 (compound 11e) (2.5 μM-5 μM, 24 h) leads to slight early-stage apoptosis in a concentration-dependent manner in K562 cells^[1].
JNK-IN-14 (1.25-5 μM, 24 h) arrests cell population in K562 at higher concentrations in comparison with SP600125, showing higher inhibitory ability.^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

521.63

C₂₇H₃₁N₅O₄S

2991432-56-3

CC(C)(N1C=C(C(C2=CC(O)=CC=C2)=N1)C3=CC=NC(NCCCNS(=O)(C4=CC=C(C=C4)O)=O)=C3)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Karim I Mersal, et al. Evaluation of novel pyrazol-4-yl pyridine derivatives possessing arylsulfonamide tethers as c-Jun N-terminal kinase (JNK) inhibitors in leukemia cells.Eur J Med Chem. 2023 Sep 15:261:115779.  [Content Brief]